The re-emergence of tuberculosis (TB) as a global health problem over the past few decades, accompanied by the rise of drug-resistant strains of Mycobacterium tuberculosis, emphasizes the need for discovery of new therapeutic drugs against this disease. The emerging serious problem both in terms of TB control and clinical management prompted us to synthesize a novel series of heterocyclic compounds and determine their activity against 3HNT protien of Mycobacterium. All compounds inhibited the growth of the 3HNT strain of mycobacterium at concentrations as low as 1 mg/mL